Insomnia - Articles and news items

Ergomed and Ferrer complete recruitment for Phase IIa insomnia clinical trial

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients with insomnia disorder…


Insomnia treatment market faces steep decline to 2016, but new drugs will aid recovery, says GlobalData

Industry news / 17 February 2015 / GlobalData

Insomnia drug sales will fall rapidly from $2.1 billion in 2013 to $1.4 billion by 2016, before steadily recovering to $1.8 billion by 2023, driven by the launch of two products, Merck & Co.’s Belsomra and Eisai’s E-2006, and an increase in the prevalent cases of insomnia, says research and consulting firm GlobalData…

Merck logo

Merck receives Complete Response Letter for Suvorexant, Merck’s investigational medicine for insomnia

Industry news, News / 1 July 2013 / Merck

“We will evaluate the requests outlined in the Complete Response Letter…”

Merck logo

Merck announces FDA acceptance of New Drug Application for Suvorexant, an investigational insomnia medicine

Industry news, News / 8 November 2012 / Merck

Merck announced that the NDA for suvorexant has been accepted for standard review…

Merck logo

Merck announces new Phase III data for suvorexant, an investigational insomnia medicine

Industry news, News / 10 September 2012 / Merck

Merck remains on target to file a New Drug Application with the FDA in 2012…

Merck logo


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...